


Supplementary Figure 1. Self-reported symptoms during COVID-19. Upon initial recruitment, subjects were asked about each symptom listed on the left during their COVID-19 illness. Each column represents a subject (n=113) with hospitalized subjects under the blue bar. Black square, symptom experienced; gray square, symptom not experienced; white square, data not collected.

Supplemental Table 1. Median (IQR) IgG antibody levels, fold RBD-ACE2 inhibition, and SARS-CoV-2 neutralization titers five weeks

after resolution of COVID-19 symptoms according to clinical and demographic characteristics in non-hospitalized subjects

	N	Anti-S A	Anti-NTD A	Anti-RBD A	Anti-N A	ACE-2 inhib.	Nab Titer
All subjects	94	19.3 (7.0, 35.2)	0.27 (0.10, 0.69)	5.1 (1.8, 12.3)	31.3 (11.0, 51.1)	72.5 (20, 287)	20 (10, 40)
Race		p=0.580	p=0.716	p=0.530	p=0.179	p=0.683	p=0.235
White		18.4 (6.7, 34.9)	0.25 (0.09, 0.73)	4.9 (1.7,11.8)	30.0 (10.4, 51.1)		20 (10, 40)
Black		26.1 (14.3, 39.9)	0.31 (0.23, 0.86)	7.0 (3.4, 14.3)	51.7 (40.6, 86.2)		30 (15, 60)
Asian	4	31.2 (15.2, 40.5)	0.47 (0.20, 0.67)	10.4 (4.2, 19.2)	25.8 (14.6, 34.2)	345.5 (75, 568.5)	60 (25, 120)
Hispanic ethnicity	5	p=0.048 39.1 (30.2, 46.0)	p=0.097 0.77 (0.56, 1.1)	p=0.100 13.4 (10.5, 14.0)	p=0.136 52.8 (43.9, 55.2)	p=0.056 310 (245, 376)	p=0.057 40 (40, 80)
ADI Index Score tertile		p=0.478	p=0.642	p=0.471	p=0.544	p=0.573	p=0.662
1 (4, 24)	33	19.0 (8.4, 31.0)	0.23 (0.11, 0.66)	4.8 (1.7, 10.9)	26.7 (12.4, 50.8)	52 (17, 131)	20 (10, 80)
2 (26, 40)	32	15.4 (5.3, 36.0)	0.26 (0.08, 0.62)	4.4 (1.6, 12.6)	30.9 (8.5, 49.4)	86 (21, 272.5)	20 (10, 40)
3 (41, 99)	29	22.7 (8.0, 43.3)	0.32 (0.13, 0.93)	7.2 (2.8, 14.0)	42.3 (24.6, 54.4)	100 (37, 310)	20 (10, 40)
Active cancer		p=0.190	p=0.925	p=0.349	p=0.779	p=0.210	p=0.312
	4	10.3 (3.7, 18.9)	0.30 (0.18, 0.40)	3.5 (1.9, 5.4)	36.0 (18.6, 41.0)	28 (15.5, 87.5)	10 (5.5, 25)
Diabetes mellitus		p=0.424	p=0.589	p=0.416	p=0.069	p=0.074	p=0.320
	7	33.2 (22.6, 77.3)	0.32 (0.06, 1.7)	10.0 (6.7, 41.6)	47.3 (30.4, 118)	219 (45, 1186)	40 (10, 80)
Vascular disease		p=0.155	p=0.056	p=0.144	p=0.2691	p=0.056	p=0.156
	4	46.6 (22.6, 70.6)	1.4 (0.63, 3.3)	22.6 (10.2, 33.3)	*	*	*
Asthma		p=0.382	p=0.755	p=0.443	p=0.106	p=0.512	p=0.813
1 10 11111	22	13.1 (5.0, 38.0)	0.29 (0.06, 0.82)	4.4 (1.1, 14.2)	23.7 (6.5, 38.4)	49.5 (14, 353)	15 (10, 40)
Immunosuppressive		p=0.376	p=0.512	p=0.338	p=0.835	p=0.412	p=0.372
medication		8.0 (5.2, 32.0)	0.12 (0.07, 0.73)	2.8 (1.2, 11.8)	37.4 (18.8, 44.4)	28 (15, 279)	10 (1, 20)
Inhaled steroid		p=0.112	p=0.018	p=0.101	p=0.935	p=0.325	p=0.050
iiiiaicu steiviu	25	33.2 (8.0, 43.3)	0.47 (0.24, 1.03)	*	33.0 (16.1, 45.7)	p=0.323 203 (34, 310)	p=0.030 20 (10, 80)

A Values are area under the curve x10⁵



Supplementary Figure 2. Antibodies to seasonal coronaviruses and SARS-CoV do not decline from five weeks to three months post COVID-19 symptom resolution. Sera from COVID-19 convalescent subjects five weeks (w) and three months (m) post symptom resolution were evaluated for IgG (reported as AUC) that bound to the spike protein of common cold coronaviruses (CCoV) OC43, HKU1, NL63 and 229E and SARS-CoV by multiplex assay. Lines connect time points for individual subjects (n=79). Paired t tests were performed ****p<0.0001.